leadf
logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals reveals 4Q revenue surge

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive its fourth quarterly revenue doubled year-over-year thanks in large part to its February acquisition of Aptevo BioTherapeutics LLC.

d’Entremont says the pharmaceutical company posted revenue of C$25.6 million in the three months ended March 31, compared to C$12.7 million in the same period a year earlier. Gross profit for the quarter jumped to C$13.3 million from C$7.7 million, and net loss increased to C$2.1 million from C$700,000.

Quick facts: Medexus Pharmaceuticals Inc

Price: 4.03 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $58.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals gets Health Canada approval to market Gleolan for...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has received a notice of compliance from Health Canada, granting the company approval to market its tumor imaging agent Gleolan in the country. d’Entremont says with Gleolan, which is essentially...

1 week, 4 days ago

2 min read